Compare VanEck Gold Miners ETF (GDX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Organon & Co. Common Stock — how do they compare? VanEck Gold Miners ETF trades at $84.49 (market cap $26.33B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: VanEck Gold Miners ETF is far larger — about 7.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Organon & Co. Common Stock for 0 Days on average.
| GDX | OGN | |
|---|---|---|
Market Cap | $26.33B | $3.62B |
Volume | 15,141,546 | 2,892,999 |
52-Week High | $115.84 | $13.81 |
52-Week Low | $68.28 | $5.70 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% on the day, with technical indicators showing a neutral to bearish bias amid mixed signals from moving averages and oscillators. The ETF's fundamental metrics are not provided in the snapshot, but recent news highlights ongoing institutional repositioning and comparisons between gold miners and physical gold. Support and resistance levels are tightly clustered around the current price, suggesting near-term consolidation.
The outlook for GDX hinges on gold price trends and interest rate movements, with potential upside from inflation hedging demand but risks from institutional selling and metal volatility. Investors face a balanced risk-reward scenario given neutral sentiment and lack of clear directional catalysts.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
